Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition
Collectively, our findings highlight early molecular and functional signatures of cardiac AL amyloidosis, with potential impact for developing improved patient biomarkers and novel therapeutics.
Authors
- Richard M. Giadone (ORCID: https://orcid.org/0000-0003-4523-3062)
- Tinuola B. Ajayi (ORCID: https://orcid.org/0000-0002-1568-7103)
- Frederick L. Ruberg (ORCID: https://orcid.org/0000-0002-6424-4413)
- Tatiana Prokaeva (ORCID: https://orcid.org/0000-0002-0790-602X)
- Josue Villegas-Galaviz (ORCID: https://orcid.org/0000-0001-5803-3188)
- Grace Ferri (ORCID: https://orcid.org/0000-0001-9377-9129)
- Vaishali Sanchorawala (ORCID: https://orcid.org/0000-0002-6307-2445)
- Pushpinder Bawa (ORCID: https://orcid.org/0000-0002-8370-3638)
- Gareth J. Morgan (ORCID: https://orcid.org/0000-0002-1275-2010)
- Camille V. Edwards (ORCID: https://orcid.org/0000-0002-2601-0667)
- Sabrina Ghosh (ORCID: https://orcid.org/0009-0003-0325-7346)
- Feiya Wang (ORCID: https://orcid.org/0000-0002-7507-6275)
- Elena S. Klimtchuk
- Andrew Staron (ORCID: https://orcid.org/0000-0003-1638-4873)
- George J. Murphy (ORCID: https://orcid.org/0000-0003-3464-793X)
Institutions
- Boston University (US)
- Boston Medical Center (US)
- Amyloidosis Foundation (US)
Publication Details
- Journal
- Amyloid
- Published
- 2025-03-25
- DOI
- https://doi.org/10.1080/13506129.2025.2478397
- Citations
- 1
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- International Myeloma Foundation
- National Institutes of Health